MedTrace Logo

Psychometric Properties of the EORTC QLQ-LC29

NCT02745691 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 523

Last updated 2019-12-13

No results posted yet for this study

Summary

The aim of the Phase 4 study is to test the scale structure, reliability, responsiveness to change and validity of the EORTC QLQ-LC29 in conjunction with the EORTC QLQ-C30 in patients diagnosed with lung cancer. Participants will be enrolled in four groups according to their primary therapy (A. Surgery, B. Radiochemotherapy, C. Targeted therapy, D. Immunotherapy). According to sample size calculations the investigators will include a total of N = 450 patients, but inflating the recruitment goal is permissible.

Conditions

Interventions

OTHER

Surgery

Thoracic surgery for lung cancer

OTHER

Radiochemotherapy

Either chemotherapy or radiotherapy alone or combination of both (either subsequent or concurrent)

OTHER

Targeted therapy

New targeted therapies for lung cancer

OTHER

Immunotherapy

New immunotherapies for lung cancer

Sponsors & Collaborators

  • University Hospital Regensburg

    lead OTHER

Principal Investigators

  • Michael Koller, PhD · University Hospital Regensburg

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-01
Primary Completion
2018-09-26
Completion
2018-09-26

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02745691 on ClinicalTrials.gov